Myfortic for the Treatment of Non-infectious Intermediate Uveitis

Inclusion Criteria: * Subjects with a documented at least 6 months history of unilateral or bilateral intermediate uveitis either idiopathic or due to non-infectious systemic disease (e.g. sarcoidosis, multiple sclerosis) * Uveitis has to be considered to be active at the timepoint of enrolment according to at least one of the following criteria: * Grade 2+ or higher for vitreous haze * Grade 2+ or higher for anterior chamber cells * Presence of cystoid macular edema in OCT * Presence of retinal vessel leakage in FA * Considered by the investigator to require systemic treatment. * At least 18 years of age * Not planning to undergo elective ocular surgery during the study * Capable of understanding the purposes and risks of the study, able to give informed consent and to comply with the study requirements * Subjects of both gender with reproductive potential who are sexually active agree to use contraception throughout the course of the study and for at least 3 months after completion of their study participation. * Women of childbearing potential have to use a highly effective method of birth control defined as one which results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, hormonal IUDs combined with barrier methods (e.g. condom, diaphragm or spermicide), sexual abstinence or vasectomised partner. * Women of childbearing age must have a negative urine pregnancy test (UPT) within 48 hours prior to starting study drug and must not be lactating. Female subjects of non-childbearing potential must meet at least one of the following criteria: 1. Postmenopausal females, defined as: c. Females over the age of 60 years. d. Females who are 45 to 60 years of age must be amenorrheic for at least 2 years. 2. Females who had a hysterectomy and/or bilateral oophorectomy. Exclusion Criteria: * Uveitis of infectious etiology * Signs of tuberculosis in chest x-ray during the past 12 months before study entry * Clinically suspected or confirmed central nervous system or ocular lymphoma * Primary diagnosis of anterior or posterior uveitis * Uncontrolled glaucoma or known steroid response * Subjects who received treatment with a systemic immunosuppressive drug, a monoclonal antibody or any other biologic therapy within 90 days prior study entry * Treatment with mycophenolate mofetil or mycophenolate sodium in the past * Treatment with a periocular steroid injection within 6 weeks prior to study entry * Presence of absolute contraindications for Decortin H and/or Myfortic as mentioned in the product informations (Appendix 1 and 2) * Presence of relative contraindications for Decortin H and/or Myfortic as mentioned in the product information (Appendix 1 and 2) if the disorder leading to the relative contraindication can not sufficiently managed by concomitant medication. * Recipients of a solid organ transplant * Subjects with lens opacities or obscured ocular media upon enrolment making unable evaluation of the posterior eye segment * Subjects with a history of herpes zoster or varicella infection within 3 months before enrollment * Active, extraocular infection requiring the prolonged or chronic use of antimicrobial agents or the history/presence of active hepatitis A, B or C * Seropositivity for human immunodeficiency virus (HIV) * Alanine transaminase (ALT), aspartate transaminase (AST), or gamma-glutamyl transferase (GGT) ≥ 2x upper limit of normal (ULN) * Severe anemia (hemoglobin \< 8 g/dL), leukopenia (white blood cell count \[WBC\] \< 2500 mm3), thrombocytopenia (platelet count \< 80,000 mm3) * Current malignancy or a history of malignancy within the previous 5 years * Pregnant or lactating women * Known allergy for fluorescein natrium * Currently participating in another clinical trial with an investigational agent in the 30 days prior to study participation and/or has not recovered from any reversible effects or side effects of prior investigational agent * Subjects with non-ocular, medically significant co-morbid conditions that impair normal activities, require systemic corticosteroids or immunosuppressives, or any medical condition that would likely have an impact on the participant´s ability to comply with the study visit schedule * Any current or history of substance abuse, psychiatric disorder or a condition that, in the opinion of the investigator, may invalidate communication